Kadin Indonesia supports the strengthening of industries in the health sector by conducting various advocacies and engaging in strategic policy recommendations to sustain Indonesia's public health and economy. In this effort, Kadin involves a number of related associations, so that the policy can accommodate the needs and interests of the national health industry.

Kadin Indonesia in the Health Sector has compiled a White Paper containing views and recommendations on the Draft Government Regulation (RPP) of Law No. 17/2023. RPP Law No. 17/2023 on pharmaceuticals and medical devices. This White Paper was prepared to provide a better understanding of the impact and implications of RPP UU No. 17/2023 on Indonesia's health sector.

This White Paper has been submitted to the Ministry of Health. This White Paper will be a valuable consideration for the government in designing and deciding policies that are in line with the needs of the Indonesian people.

Kadin Indonesia is committed to being a partner for entrepreneurs and associations, and continues to support the development of a quality health sector in Indonesia. Strong collaboration and cooperation can achieve common goals for the welfare and health of all Indonesian people.

In this regard, Kadin Indonesia also has a Health programme that seeks to target global investment from the private sector in the healthcare industry. Some of its programmes include One Shot Campaign and Business Law : Healthcare Market.

The programme will focus on pillars such as research and development (R&D) of vaccines, therapeutics and diagnostics, regional healthcare supply harmonisation, partnerships in genomics, digital surveillance and supply chain connectivity for healthcare resilience in Indonesia. 

Informasi lengkap mengenai Buku Putih Rekomendasi RPP 2023 UU Kesehatan No.17 Thaun 2023 Sektor Farmasi dan Alat Kesehatan dapat diperoleh here.